Navigation Links
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Date:7/1/2009

EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease.

Under the terms of the agreement, Synageva will use its proprietary Synageva Expression Platform (SEP(TM)) technology and its expertise to produce and develop a therapeutic monoclonal antibody. SEP(TM) is an integrated platform of proprietary systems for protein production, processing and purification.

"Morphotek is an industry leader in antibody discovery and development," said Sanj K. Patel, President and Chief Executive Officer of Synageva BioPharma Corporation. "Their commitment to utilizing Synageva's platform is a testament to the strength of our science and product development capabilities and we are excited about the potential for this collaboration."

"We have a rich pipeline of antibody products such as MORAb-003, or farletuzumab, for ovarian cancer in Phase III, MORAb-009 for pancreatic cancer in Phase II and MORAb-004 that is pan-cancer specific in Phase I," stated Philip M. Sass, PhD, Executive Vice President and Chief Operating Officer, Morphotek, Inc. "We are always exploring new ways that may enhance the manufacturing process for our antibody products as a means to fulfill Eisai's hhc mission."

Through the use of its proprietary MORPHODOMA(R) technology, Morphotek develops optimized antibodies, including antibodies optimized for affinity and/or titer, for therapeutic applications and high-titer manufacturing cell lines. The company has assembled a portfolio of lead human and humanized antibodies to antigens associated with cancer, neovascular, inflammatory and infectious disease. The antibodies within the company's pipeline are targeted against a
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
2. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
3. Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... NY (PRWEB) September 18, 2014 Whitehouse ... negotiations with Salem Realty Group and has acquired an ... space within the Salem Executive Complex adjacent to its ... was held on Friday September 5th. Whitehouse Labs is ... the entire space specifically for package testing. The prime ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. (NASDAQ: ... and marketer of patent protected regenerative biomaterials and ... publication of another peer-reviewed clinical study.    ... Multi-center Randomized Controlled Clinical Trial Evaluating the Use ... Allografts and Multi-layer Compression Therapy vs. Multi-layer Compression ...
(Date:9/17/2014)... 17, 2014 Immunomic Therapeutics, Inc. announced ... (SBIR) grant to support the continued preclinical development of ... with approximately $255,000 over one year to conduct vaccine ... food allergy, affect over one million Americans and are ... Tree nut exposure is also a risk for peanut ...
Breaking Biology Technology:Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Oncothyreon Announces Proposed Public Offerings 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3
... 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: ... for 2011, highlighting its continued focus on strong ... Company,s diabetes franchise, notably through advancing the investigational ... other value-driving development programs. Daniel M. Bradbury, president ...
... BioLife Solutions, Inc. (OTC Bulletin Board: BLFS ) ... and Chief Executive Officer Mike Rice, to summarize the continued ... strategic growth initiatives.   (Logo:   http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO ) ... of $575,000 for the fourth quarter of 2010, an increase ...
... The Jackson Laboratory (JAX), Sackler School of Graduate Biomedical Sciences ... a new mammalian genetics track for Ph.D. students. The joint ... and Tufts. Combining the faculty and resources of the genetics ... the faculty and resources at JAX, with its emphasis on ...
Cached Biology Technology:Amylin to Advance Key Value-Driving Opportunities in 2011 2Amylin to Advance Key Value-Driving Opportunities in 2011 3BioLife Solutions CEO Issues 2010 Corporate Update 2BioLife Solutions CEO Issues 2010 Corporate Update 3The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 2The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 3
(Date:9/17/2014)... have obtained the first partial genome sequence of an ... at the site of the Montsoriu Castle in Girona, ... closely related to today,s Iberian pig. Researchers also discard ... Iberian pigs. , The study, published in Heredity ... species, and particularly on that of the Iberian breed, ...
(Date:9/17/2014)... September 17, 2014 Researchers at UTSouthwestern Medical ... the circulating protein apolipoprotein E, called apoE3, helps repair ... called apoE4, do not get the benefit of this ... , "We believe that we have identified one mechanism ... why a genetic variant, apoE4, is detrimental," said ...
(Date:9/17/2014)... 1960s. The typical development phases of trees and stands ... as much as 70 percent. This was the outcome ... Universitt Mnchen based on long-term data from experimental forest ... findings were published recently in Nature Communications . ... topic, with the very survival of large forest ecosystems ...
Breaking Biology News(10 mins):Iberian pig genome remains unchanged after 5 centuries 2Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... is available in German . , ... , is able to rapidly ,and efficiently detoxify chemical ... the Tokyo subway attacks in 1995. A detailed understanding ... is ,necessary for efforts aiming to improve their properties. ...
... of Canada,s southern Rockies are a more distinct breed ... by University of Calgary researchers that is shedding light ... In a study published in the current issue of ... Design PhD candidate Byron Weckworth and his research group ...
... release is available in French . ... is pleased to announce that Concordia,s Centre for Structural ... research done by nine universities which are part of ... focusing on the conversion of agricultural waste into biofuel ...
Cached Biology News:Structure of enzyme against chemical warfare agents determined 2Mountain caribou's ancient ancestry revealed 2
... offers major advantages over other RNA precipitation methods ... or carbohydrates. It is the method of choice ... from RNA preparations. Note, LiCl precipitation may not ... If the RNA is to be used for ...
... Antifade Kit is an aqueous-based mounting reagent ... dyes. This formulation of antifade minimizes the ... Blue fluorophores that is often seen with ... available with the blue-fluorescent nucleic acid ...
in vitro Translation, Accessory Products...
Mouse Collagen IV...
Biology Products: